Lantern Pharma to Debut Public Demonstration of withZeta.ai – A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

Key Takeaways

• Lantern will demo withZeta.ai live on April 30, 2026.
• Platform targets rare cancers using multi‑agent AI co‑scientist technology.
• AI drug discovery market projected >$15 billion by 2030, 30% CAGR.
• Subscription model offers academic, enterprise tiers for global research access.
• CEO Panna Sharma leads interactive walkthrough with live Q&A.

Pulse Analysis

Lantern Pharma’s upcoming public demonstration of withZeta.ai underscores a broader shift in oncology toward AI‑augmented research. While traditional drug discovery can take years and billions of dollars, the platform promises to compress timelines by simultaneously querying clinical trials, literature, and molecular data. By integrating a proprietary rare‑cancer ontology and generative chemistry models, withZeta.ai aims to fill the long‑standing gap where rare cancers receive limited investment due to high development costs and uncertain returns.

The AI‑driven drug discovery market is projected to exceed $15 billion by 2030, growing at more than 30% annually. This rapid expansion is fueled by advances in machine learning, cloud computing, and the increasing availability of high‑quality biomedical datasets. Lantern’s subscription‑based approach—offering academic, introductory, and enterprise tiers—mirrors successful SaaS models in other tech sectors, providing a scalable, non‑dilutive revenue stream while democratizing access to cutting‑edge research tools for institutions worldwide.

For investors and the biomedical community, the live, unscripted walkthrough serves as a transparency exercise and a proof point for commercial viability. If the platform can reliably generate actionable insights in real time, it could accelerate rare‑cancer drug pipelines, attract partnership opportunities, and enhance Lantern’s valuation beyond its current clinical‑stage assets. The event therefore not only showcases technology but also signals a potential new growth engine for the company and a catalyst for broader adoption of AI co‑scientist platforms in pharma.